Winton Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-9,943
| Closed | -$1.22M | – | 1222 |
|
|
2025
Q4 | $1.22M | Sell |
9,943
-56,799
| -85% | -$6.9M | 0.04% | 413 |
|
|
2025
Q3 | $7.41M | Buy |
66,742
+21,427
| +47% | +$2.44M | 0.28% | 89 |
|
|
2025
Q2 | $5.02M | Buy |
+45,315
| New | +$4.82M | 0.26% | 96 |
|
|
2025
Q1 | – | Sell |
-3,924
| Closed | -$362K | – | 715 |
|
|
2024
Q4 | $362K | Buy |
+3,924
| New | +$353K | 0.02% | 495 |
|
|
2024
Q3 | – | Sell |
-8,800
| Closed | -$604K | – | 685 |
|
|
2024
Q2 | $604K | Buy |
8,800
+3,043
| +53% | +$203K | 0.04% | 399 |
|
|
2024
Q1 | $422K | Buy |
+5,757
| New | +$443K | 0.03% | 490 |
|
|
2023
Q4 | – | Sell |
-2,938
| Closed | -$220K | – | 779 |
|
|
2023
Q3 | $220K | Buy |
+2,938
| New | +$226K | 0.02% | 633 |
|
|
2023
Q2 | – | Sell |
-2,478
| Closed | -$206K | – | 903 |
|
|
2023
Q1 | $206K | Sell |
2,478
-4,710
| -66% | -$390K | 0.01% | 897 |
|
|
2022
Q4 | $617K | Sell |
7,188
-39,629
| -85% | -$3.14M | 0.04% | 569 |
|
|
2022
Q3 | $2.89M | Sell |
46,817
-42,604
| -48% | -$2.69M | 0.19% | 119 |
|
|
2022
Q2 | $5.53M | Buy |
89,421
+47,985
| +116% | +$2.97M | 0.29% | 58 |
|
|
2022
Q1 | $2.46M | Buy |
41,436
+9,834
| +31% | +$629K | 0.13% | 200 |
|
|
2021
Q4 | $2.29M | Buy |
+31,602
| New | +$2.18M | 0.14% | 183 |
|
|
2021
Q1 | – | Sell |
-12,397
| Closed | -$722K | – | 1395 |
|
|
2020
Q4 | $722K | Sell |
12,397
-52,631
| -81% | -$3.18M | 0.05% | 588 |
|
|
2020
Q3 | $4.11M | Sell |
65,028
-25,109
| -28% | -$1.74M | 0.13% | 193 |
|
|
2020
Q2 | $6.93M | Buy |
90,137
+32,089
| +55% | +$2.46M | 0.18% | 111 |
|
|
2020
Q1 | $4.34M | Buy |
+58,048
| New | +$4.01M | 0.11% | 302 |
|
|
2019
Q2 | – | Sell |
-3,405
| Closed | -$221K | – | 1192 |
|
|
2019
Q1 | $221K | Sell |
3,405
-803
| -19% | -$53.4K | ﹤0.01% | 925 |
|
|
2018
Q4 | $263K | Sell |
4,208
-181
| -4% | -$12.7K | 0.01% | 709 |
|
|
2018
Q3 | $339K | Sell |
4,389
-1,182
| -21% | -$89.3K | 0.01% | 770 |
|
|
2018
Q2 | $395K | Sell |
5,571
-2,103
| -27% | -$149K | 0.01% | 726 |
|
|
2018
Q1 | $579K | Buy |
7,674
+1,079
| +16% | +$85.8K | 0.02% | 703 |
|
|
2017
Q4 | $472K | Sell |
6,595
-8,436
| -56% | -$641K | 0.01% | 513 |
|
|
2017
Q3 | $1.22M | Sell |
15,031
-161,648
| -91% | -$12.4M | 0.04% | 378 |
|
|
2017
Q2 | $12.5M | Sell |
176,679
-443,922
| -72% | -$29.5M | 0.37% | 83 |
|
|
2017
Q1 | $42.2M | Sell |
620,601
-17,383
| -3% | -$1.22M | 1.15% | 13 |
|
|
2016
Q4 | $45.7M | Sell |
637,984
-271,529
| -30% | -$20.2M | 1.51% | 6 |
|
|
2016
Q3 | $72M | Sell |
909,513
-136,787
| -13% | -$11.1M | 1.24% | 6 |
|
|
2016
Q2 | $87.3M | Sell |
1,046,300
-181,434
| -15% | -$16.1M | 1.44% | 2 |
|
|
2016
Q1 | $113M | Sell |
1,227,734
-32,131
| -3% | -$2.9M | 1.22% | 3 |
|
|
2015
Q4 | $127M | Buy |
1,259,865
+301,813
| +32% | +$31.4M | 1.13% | 6 |
|
|
2015
Q3 | $94.1M | Buy |
958,052
+256,291
| +37% | +$28.5M | 0.74% | 18 |
|
|
2015
Q2 | $82.2M | Buy |
701,761
+312,838
| +80% | +$34.2M | 0.75% | 24 |
|
|
2015
Q1 | $38.2M | Buy |
388,923
+276,220
| +245% | +$28M | 0.3% | 125 |
|
|
2014
Q4 | $10.6M | Sell |
112,703
-119,501
| -51% | -$12.4M | 0.13% | 249 |
|
|
2014
Q3 | $24.7M | Sell |
232,204
-272,256
| -54% | -$26.7M | 0.18% | 223 |
|
|
2014
Q2 | $41.8M | Buy |
+504,460
| New | +$39.3M | 0.29% | 141 |
|
Other funds holding GILD
Winton Group's GILD Position: Q1 2026 in Review
Winton Group sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 9,943 shares — an estimated $1.22M sold.
Winton Group first reported a position in GILD in Q2 2014 and held it in 37 quarters. The position peaked at $127M in Q4 2015. 2,320 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Winton Group reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
- Winton Group sold 9,943 Gilead Sciences shares in Q1 2026, an estimated $1.22M.
- Winton Group first reported a position in Gilead Sciences in Q2 2014 and held it in 37 quarters.
- Winton Group's Gilead Sciences position peaked at $127M in Q4 2015.
- 2,320 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.